scispace - formally typeset
Search or ask a question
Topic

Cancer cell

About: Cancer cell is a research topic. Over the lifetime, 93402 publications have been published within this topic receiving 3512390 citations. The topic is also known as: cancerous cell & tumor cell.


Papers
More filters
Journal ArticleDOI
18 Feb 2011-Small
TL;DR: It is demonstrated that the PEI-GO is an excellent nanocarrier for effective delivery of siRNA and chemical drugs, and that sequential delivery of the siRNAs and the anticancer drug doxorubicin by PEi-GO into cancer cells exhibits a synergistic effect, which leads to a signifi cantly enhanced chemotherapy effi cacy.
Abstract: PEI GO The RNA interference (RNAi) technique, an effective method to inhibit protein expression by targeted cleavage of messenger RNA (mRNA), has made substantial progress since the fi rst demonstration of gene knockdown in mammalian cells. [ 1 ] Short interfering RNA (siRNA) induces specifi c silencing of targeted protein, thus offering signifi cant potential in overcoming multiple drug resistance (MDR) of cancer cells. [ 2 ] For example, Bcl-2 protein, one of the main antiapoptotic defense proteins, is closely related to the MDR of cancer cells. [ 3 ] Knockdown of the Bcl-2 protein expression level in cancer cells by Bcl-2-targeted siRNA would effectively overcome the MDR of cancer cells and sensitize cancer cells to anticancer drugs. [ 3 d, 4 ] Herein, we report sequential delivery of Bcl-2-targeted siRNA and the anticancer drug doxorubicin (DOX) using polyethylenimine (PEI)-functionalized graphene oxide (PEI-GO). We demonstrate that the PEI-GO is an excellent nanocarrier for effective delivery of siRNA and chemical drugs, and that sequential delivery of the siRNA and DOX by PEI-GO into cancer cells exhibits a synergistic effect, which leads to a signifi cantly enhanced chemotherapy effi cacy. To the best of our knowledge, this is the fi rst report on applications of GO-based nanovectors for delivery of siRNA, and sequential delivery of siRNA and anticancer drugs into cancer cells. Graphene, a newly discovered 2D nanomaterial, has been studied extensively due to its fundamental importance and potential applications, [ 5 ] while exploration of its biomedical applications has just started. [ 6 ] Noncovalent adsorption through π – π stacking, electrostatic, and other molecular interactions has proven to be effective for immobilizing chemical drugs, single-stranded DNA, and RNA onto GO sheets. [ 6 a–e]

530 citations

Journal ArticleDOI
TL;DR: The role of TGF-β signaling in cell cycle arrest, apoptosis, EMT and cancer cell metastasis is considered and recent insights into the multistep and dynamically controlled process of T GF-β-induced EMT are highlighted.
Abstract: Transforming growth factor β (TGF-β) is a secreted cytokine that regulates cell proliferation, migration, and the differentiation of a plethora of different cell types. Consistent with these findings, TGF-β plays a key role in controlling embryogenic development, inflammation, and tissue repair, as well as in maintaining adult tissue homeostasis. TGF-β elicits a broad range of context-dependent cellular responses, and consequently, alterations in TGF-β signaling have been implicated in many diseases, including cancer. During the early stages of tumorigenesis, TGF-β acts as a tumor suppressor by inducing cytostasis and the apoptosis of normal and premalignant cells. However, at later stages, when cancer cells have acquired oncogenic mutations and/or have lost tumor suppressor gene function, cells are resistant to TGF-β-induced growth arrest, and TGF-β functions as a tumor promotor by stimulating tumor cells to undergo the so-called epithelial-mesenchymal transition (EMT). The latter leads to metastasis and chemotherapy resistance. TGF-β further supports cancer growth and progression by activating tumor angiogenesis and cancer-associated fibroblasts and enabling the tumor to evade inhibitory immune responses. In this review, we will consider the role of TGF-β signaling in cell cycle arrest, apoptosis, EMT and cancer cell metastasis. In particular, we will highlight recent insights into the multistep and dynamically controlled process of TGF-β-induced EMT and the functions of miRNAs and long noncoding RNAs in this process. Finally, we will discuss how these new mechanistic insights might be exploited to develop novel therapeutic interventions.

529 citations

Journal ArticleDOI
29 May 2009-Cell
TL;DR: In this article, the authors used high-throughput RNA interference (RNAi) to identify synthetic lethal interactions in cancer cells harboring mutant KRAS, the most commonly mutated human oncogene, and demonstrate the potential of RNAi screens for discovering functional dependencies created by oncogenic mutations that may enable therapeutic intervention for cancers with "undruggable" genetic alterations.

527 citations

Journal ArticleDOI
TL;DR: The connection between cancerous transformation and glycosylation which may help to understand and control the abnormal biology of tumor cells is revealed.

526 citations

Journal ArticleDOI
TL;DR: The results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury.
Abstract: Many agents are active in multiple myeloma, but the majority of patients relapse. This clinical pattern suggests most cancer cells are eliminated, but cells with the clonogenic potential to mediate tumor regrowth are relatively chemoresistant. Our previous data suggested that CD138(+) multiple myeloma plasma cells cannot undergo long-term proliferation but rather arise from clonogenic CD138(neg) B cells. We compared the relative sensitivity of these distinct cell types to clinical antimyeloma agents and found that dexamethasone, lenadilomide, bortezomib, and 4-hydroxycyclophosphamide inhibited CD138(+) multiple myeloma plasma cells but had little effect on CD138(neg) precursors in vitro. We further characterized clonogenic multiple myeloma cells and stained cell lines using the Hoechst side population and Aldefluor assays. Each assay identified CD138(neg) cells suggesting that they possess high drug efflux capacity and intracellular drug detoxification activity. We also found that multiple myeloma cells expressing the memory B-cell markers CD20 and CD27 could give rise to clonogenic multiple myeloma growth in vitro and engraft immunodeficient nonobese diabetes/severe combined immunodeficient mice during both primary and secondary transplantation. Furthermore, both the side population and Aldefluor assays were capable of identifying circulating clonotypic memory B-cell populations within the peripheral blood of multiple myeloma patients. Our results suggest that circulating clonotypic B-cell populations represent multiple myeloma stem cells, and the relative drug resistance of these cells is mediated by processes that protect normal stem cells from toxic injury.

526 citations


Network Information
Related Topics (5)
Apoptosis
115.4K papers, 4.8M citations
94% related
Cell culture
133.3K papers, 5.3M citations
92% related
Signal transduction
122.6K papers, 8.2M citations
90% related
Cancer
339.6K papers, 10.9M citations
89% related
Cytotoxic T cell
92.4K papers, 4.7M citations
87% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
20233,549
20225,645
20216,773
20207,065
20196,724
20186,305